{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:56:32Z","timestamp":1788389792159,"version":"build-2803163510"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The introduction of endovascular surgery has led to frequent stent use, although in-stent restenosis (ISR) remains a challenging issue. Drug-coated balloon (DCB) and conventional balloon angioplasty (BA) are common endovascular procedures for addressing ISR in the femoropopliteal artery. However, there is controversy regarding which procedure provides the greatest benefit to patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched for prospective controlled trials that compared DCB and BA for patients with ISR in the femoropopliteal artery. The study has been approved by Ethics Committee of Wuhan Central Hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The meta-analysis included 6 prospective trials with 541 patients. We found that DCB use was associated with significant reductions in binary restenosis at 6\u200amonths (relative risk [RR]: 0.45, 95% confidence interval [CI]: 0.33\u20130.63; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001), binary restenosis at 1\u200ayear (RR: 0.44, 95% CI: 0.34\u20130.57; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001), target lesion revascularization (TLR) at 6\u200amonths (RR: 0.36, 95% CI: 0.20\u20130.65; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0006), and TLR at 1\u200ayear (RR: 0.38, 95% CI: 0.27\u20130.54; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001). The DCB group also had significantly better clinical improvement (RR: 1.39, 95% CI: 1.13\u20131.71; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.002), although we did not detect inter-group differences in terms of death, target vessel thrombosis, or ipsilateral amputation. The brand of DCB may a cause of heterogeneity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Relative to BA, DCB use increases the durability of treatment for ISR in the femoropopliteal artery, based on significant reductions in binary restenosis and TLR at 6\u201312\u200amonths after the procedure. Furthermore, DCB use was associated with better clinical improvement. However, additional randomized controlled trials are needed to validate these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025599","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T13:18:41Z","timestamp":1619011121000},"page":"e25599","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Drug-coated balloon angioplasty versus balloon angioplasty for treating patients with in-stent restenosis in the femoropopliteal artery"],"prefix":"10.1097","volume":"100","author":[{"given":"Shaobo","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Vascular Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-7882","authenticated-orcid":false,"given":"Tao","family":"He","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihui","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/1526602816645080","article-title":"Single-center experience with Lutonix drug-coated balloons in infrapopliteal arteries","volume":"23","author":"Steiner","year":"2016","journal-title":"J Endovasc Ther"},{"key":"R2-20250504","first-page":"e686","article-title":"2016\u200aAHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/VHRM.S81122","article-title":"Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease","volume":"12","author":"Herten","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"R4-20250504","first-page":"501","article-title":"The role of drug-coated balloons in in-stent restenosis","volume":"58","author":"Andrassy","year":"2017","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4244\/EIJY14M08_12","article-title":"Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study","volume":"11","author":"Unverdorben","year":"2015","journal-title":"EuroIntervention"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa061254","article-title":"Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter","volume":"355","author":"Scheller","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2011.09.036","article-title":"Classification and clinical impact of restenosis after femoropopliteal stenting","volume":"59","author":"Tosaka","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1526602814564383","article-title":"Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial","volume":"22","author":"Scheinert","year":"2015","journal-title":"J Endovasc Ther"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.jacc.2012.07.033","article-title":"Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis","volume":"60","author":"Stabile","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/CIRCULATIONAHA.107.735985","article-title":"Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial","volume":"118","author":"Werk","year":"2008","journal-title":"Circulation"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"S395","DOI":"10.1097\/01.RVI.0000094613.61428.a9","article-title":"Society of Interventional Radiology Technology Assessment C. Reporting standards for clinical evaluation of new peripheral arterial revascularization devices","volume":"14","author":"Sacks","year":"2003","journal-title":"J Vasc Interv Radiol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2288-11-41","article-title":"Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics","volume":"11","author":"Bowden","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"e006321","DOI":"10.1161\/JAHA.117.006321","article-title":"ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): a randomized trial","volume":"25","author":"Ott","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1161\/CIRCULATIONAHA.115.017364","article-title":"Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized Femoral Artery In-Stent Restenosis (FAIR) trial","volume":"132","author":"Krankenberg","year":"2015","journal-title":"Circulation"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jcin.2016.04.012","article-title":"Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial","volume":"9","author":"Kinstner","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jcin.2013.07.010","article-title":"Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery)","volume":"6","author":"Liistro","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1583\/13-4420R.1","article-title":"Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study","volume":"21","author":"Liistro","year":"2014","journal-title":"J Endovasc Ther"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/1526602820907917","article-title":"Paclitaxel-coated balloon vs uncoated balloon angioplasty for treatment of in-stent restenosis in the superficial femoral and popliteal arteries: the COPA CABANA trial","volume":"27","author":"Tepe","year":"2020","journal-title":"J Endovasc Ther"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2015.09.063","article-title":"Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA","volume":"66","author":"Laird","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R22-20250504","first-page":"508","article-title":"In-stent restenosis management: the best is yet to come","volume":"58","author":"van den Berg","year":"2017","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"R23-20250504","first-page":"217","article-title":"Drug-coated balloons: current outcomes and future directions","volume":"6","author":"Kondapalli","year":"2017","journal-title":"Interv Cardiol Clin"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcin.2016.02.015","article-title":"In-stent restenosis after femoropopliteal interventions with drug-eluting stents: same but different?","volume":"9","author":"Sobieszczyk","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R25-20250504","first-page":"CD012510","article-title":"Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries","volume":"26","author":"Kayssi","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/1526602815626557","article-title":"Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability","volume":"23","author":"Katsanos","year":"2016","journal-title":"J Endovasc Ther"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijsu.2017.04.057","article-title":"Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis","volume":"42","author":"Wu","year":"2017","journal-title":"Int J Surg"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ccd.28176","article-title":"Drug-coated balloon versus plain old balloon angioplasty in femoropopliteal disease: an updated meta-analysis of randomized controlled trials","volume":"94","author":"Anantha-Narayanan","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"e0143658","DOI":"10.1371\/journal.pone.0143658","article-title":"Feasibility and clinical outcomes of peripheral drug-coated balloon in high-risk patients with femoropopliteal disease","volume":"10","author":"Taniyama","year":"2015","journal-title":"PLoS One"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eclinm.2019.09.004","article-title":"Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: a systematic review and meta-analysis of randomised controlled trials","volume":"16","author":"Christof","year":"2019","journal-title":"EClinicalMedicine"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejvs.2016.10.002","article-title":"Femoropopliteal in-stent restenosis repair: midterm outcomes after paclitaxel eluting balloon use (PLAISIR Trial)","volume":"53","author":"Bague","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1583\/13-4308MR.1","article-title":"Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study","volume":"20","author":"Gandini","year":"2013","journal-title":"J Endovasc Ther"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1177\/1526602814564385","article-title":"Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial","volume":"22","author":"Bosiers","year":"2015","journal-title":"J Endovasc Ther"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00270-012-0479-9","article-title":"Neointimal hyperplasia after Silverhawk atherectomy versus percutaneous transluminal angioplasty (PTA) in femoropopliteal stent reobstructions: a controlled, randomized pilot trial","volume":"36","author":"Brodmann","year":"2012","journal-title":"CardioVasc Intervent Radiol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1148\/radiol.2481071159","article-title":"Conventional balloon angioplasty versus peripheral cutting balloon angioplasty fortreatment of femoropopliteal artery in-stent restenosis: initial experience","volume":"248","author":"Dick","year":"2008","journal-title":"Radiology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:10:37Z","timestamp":1746339037000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025599"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":35,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025599","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"2020-08-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}